Literature DB >> 26260813

miRNA-15a/16: as tumor suppressors and more.

Enyu Huang1, Ronghua Liu1, Yiwei Chu1,2.   

Abstract

Since their first discovery in chronic lymphocytic leukemia, miR-15a and miR-16 have been reported to act as tumor suppressors or potential oncomiRs in different types of cancer. This review summarizes the history, biological properties and the important functions of these two miRNAs in cancer. It also introduces their roles as regulators of immune responses and angiogenesis, endogenous controls as well as potential targets and hallmarks of cancer.

Entities:  

Keywords:  angiogenesis; cancer hallmarks; cancer therapy; immune regulator; miRNA

Mesh:

Substances:

Year:  2015        PMID: 26260813     DOI: 10.2217/fon.15.101

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  33 in total

1.  Expression profiling of microRNAs and isomiRs in conventional central chondrosarcoma.

Authors:  Antonina Parafioriti; Ingrid Cifola; Clarissa Gissi; Eva Pinatel; Laura Vilardo; Elisabetta Armiraglio; Andrea Di Bernardo; Primo Andrea Daolio; Armando Felsani; Igea D'Agnano; Anna Concetta Berardi
Journal:  Cell Death Discov       Date:  2020-06-10

2.  Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression.

Authors:  Lei Zhang; Lin Zhou; Meng Shi; Yong Kuang; Lei Fang
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

3.  miR-15a and miR-24-1 as putative prognostic microRNA signatures for pediatric pilocytic astrocytomas and ependymomas.

Authors:  M Braoudaki; G I Lambrou; K Giannikou; S A Papadodima; A Lykoudi; K Stefanaki; G Sfakianos; A Kolialexi; F Tzortzatou-Stathopoulou; M Tzetis; S Kitsiou-Tzeli; E Kanavakis
Journal:  Tumour Biol       Date:  2016-01-26

4.  Pten and Dicer1 loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma.

Authors:  Xiyin Wang; Jillian R H Wendel; Robert E Emerson; Russell R Broaddus; Chad J Creighton; Douglas B Rusch; Aaron Buechlein; Francesco J DeMayo; John P Lydon; Shannon M Hawkins
Journal:  Oncogene       Date:  2020-08-25       Impact factor: 9.867

5.  [The regulatory role of microRNA in osteogenic differentiation of mesenchymal stem cells and its application as a therapeutic target and diagnostic tool in orthopedic diseases].

Authors:  Xiaolong Li; Qingquan Kong
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-10-15

6.  MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.

Authors:  Fei Li; Yan Xu; Shuhui Deng; Zengjun Li; Dehui Zou; Shuhua Yi; Weiwei Sui; Mu Hao; Lugui Qiu
Journal:  Oncotarget       Date:  2015-11-10

7.  Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study.

Authors:  Armin Soave; Felix K-H Chun; Timo Hillebrand; Michael Rink; Lars Weisbach; Bettina Steinbach; Margit Fisch; Klaus Pantel; Heidi Schwarzenbach
Journal:  Oncotarget       Date:  2017-05-07

8.  Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer.

Authors:  Muralidharan Jayaraman; Rangasudhagar Radhakrishnan; Cara A Mathews; Mingda Yan; Sanam Husain; Katherine M Moxley; Yong Sang Song; Danny N Dhanasekaran
Journal:  Genes Cancer       Date:  2017-05

9.  Serum microRNA expression profiling in patients with multiple system atrophy.

Authors:  Kodai Kume; Hisakazu Iwama; Kazushi Deguchi; Kazuyo Ikeda; Tadayuki Takata; Yohei Kokudo; Masaki Kamada; Keiko Fujikawa; Kayo Hirose; Hisashi Masugata; Tetsuo Touge; Tsutomu Masaki
Journal:  Mol Med Rep       Date:  2017-11-07       Impact factor: 2.952

10.  miR‑21‑5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3.

Authors:  Jun Chen; Chao Zhou; Junhe Li; Xiaojun Xiang; Ling Zhang; Jun Deng; Jianping Xiong
Journal:  Int J Mol Med       Date:  2018-01-18       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.